{"nctId":"NCT00760019","briefTitle":"Inflammation and Vascular Function in Atherosclerosis","startDateStruct":{"date":"2005-08"},"conditions":["Atherosclerosis"],"count":58,"armGroups":[{"label":"Salsalate first, then Placebo","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: salsalate"]},{"label":"Placebo first, then Salsalate","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: placebo"]}],"interventions":[{"name":"salsalate","otherNames":["Disalcid"]},{"name":"placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Non-smoking adult subjects with known atherosclerosis\n\nExclusion Criteria:\n\n* Uncontrolled hypertension (\\> 140/90 mmHg)\n* Untreated hypercholesterolemia (LDL \\> 160 mg/dL)\n* Diabetes mellitus\n* Alanine Aminotransferase \\> 150\n* Creatinine \\> 1.4 mg/dL\n* Concommitant use of warfarin","healthyVolunteers":true,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Flow-mediated, Endothelium-dependent Vasodilation","description":"Flow-mediated, endothelium-dependent vasodilation (percentage increase in brachial artery diameter after a 5 minute ischemic stimulus) measured at the end of placebo treatment and end of salsalate treatment were compared.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.8","spread":null},{"groupId":"OG001","value":"8.7","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":58},"commonTop":["Tinnitus"]}}}